Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Prestige Brands Holdings — Q3 FY2017 Earnings Presentation
28 slides from Prestige Consumer Healthcare's earnings presentation, Feb 2, 2017
Slide 1: Review of Third Quarter FY 17 Results
Exhibit 99.2 —_ e PrestigeBrands Review of Third Quarter FY 17 Results February 2, 2017
Slide 2: Forward-looking statements
This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenue growth, adjusted EPS, and adjusted free cash flow; the impact of th
Slide 3: Agenda for Today's Discussion
Agenda for Today's Discussion |. Performance Highlights Il. MeA Update Ill. Financial Overview IV. FY 17 Outlook
Slide 4: I. Performance Highlights
I. Performance Highlights
Slide 5: Q3 performance highlights
Q3 Revenue of $216.8 million, up 8.3% versus PY Q3 — Organic growth of 2.8%(1) on a constant currency basis — Revenue growth of 4.3%(1) for Invest for Growth* portfolio — International revenue up 6.5% in Q3 with particular strength in Care Pharma Gross Margin of 57.5% in line with Q2 and expecta
Slide 6: Strong Financial Performance in YTD FY 17
Strong Financial Performance in YTD 93 FY 17 Revenue of $641.4 million, up 7.2% versus YTD 93 FY 16 Organic Revenue growth of +1.0%") on a constant currency basis Adjusted EPS of $1.83"), up 10.9% versus YTD 93 FY 16 Adjusted Free Cash Flow of $149.1 million), up 10.7% versus YTD 93 FY 16 ee réstige
Slide 7: Consumption and organic revenue growth
FY 17 Source: Data reflect retail dollar sales percentage growth versus prior period for consumption growth and organic revenue growth. IRI MULO + C-Store retail dollar sales growth for relevant period. FY 15 and FY 16 data shown as previously presented for Core OTC. Q1, Q2, and Q3 FY 17 data for In
Slide 8: II. M&A Update
ll. M&A Update
Slide 9: Recent acquisitions and divestitures
July 2016 December 2016 December 2016 December 2016 February 2016 January 2017 * Announcement date $225MM $825MM
Slide 10: Portfolio transformation since FY 2013
~$625 ~$800 ~$1,000 FY 2013 FY 2016 Pro Forma ~65% ~80% ~85% FY 2013 FY 2016 Pro Forma ~65% ~70% ~75% FY 2013 FY 2016 Pro Forma + ~1.3x + ~5% pts + ~5% pts 2 5 7 FY 2013 FY 2016 Pro Forma Dollar values in millions Note: All charts refer to Total Revenue or Revenue mix as % of total. + 1.4x
Slide 11: Pro forma revenue by brand
~$275 ~$120 ~$120 ~$110 ~$110 Dollar values in millions Note: Figures represent approximate annualized Total Revenues pro forma for C.B. Fleet acquisition. ~$100 ~$150
Slide 12: Women's health brands
Temporary relief of minor vaginal irritation and itching pH-balanced, gentle formulas Cleanses odor-causing bacteria pH-balanced, alcohol-free and hypoallergenic Quick and discreet pH-balanced, alcohol-free and hypoallergenic Neutralizes odor and absorbs moisture Hypoallergenic and i
Slide 13: Fleet brand overview
#1 Doctor recommended brand with leading market position in Enema and Liquid Glycerin Suppository categories Brand is known for quality, safety, efficacy and reliability Fleet product forms deliver highly effective relief in a fraction of the time it takes for traditional oral tablet laxatives
Slide 14: Fleet acquisition strategic priorities and synergies
Leverage Prestige’s scale to expand distribution Strengthen and accelerate international growth Invest meaningfully in Fleet’s brands and accelerate new product pipeline Broaden established leadership in women’s health Optimize operations to derive significant synergies over time Identif
Slide 15: III. Financial Overview
Ill. Financial Ouerview “Summer's Eve Clear eyes.
Slide 16: Solid overall financial performance in the quarter
Solid overall financial performance in the quarter − Revenue of $216.8 million, an increase of 8.3% − Adjusted EPS of $0.61(2), up 15.1% − Adjusted Free Cash Flow of $49.6 million(2), an increase of 8.3% $216.8 $74.9 $49.6 $200.2 $69.7 $45.8 Total Revenue Adjusted EBITDA Adjusted EPS Adjusted Free
Slide 17: Q3 income statement summary
Revenue growth of +8.3% – Organic growth of 2.8% excluding the impact of Fx(1) – DenTek contributed $17.3 million of revenue during the quarter Gross Margin of 57.5% A&P 14.2% of Revenue, or $30.7 million Adjusted EBITDA Margin of 34.6%(2) Adjusted Net Income +15.1%(2) over Q3 FY 16, ahead
Slide 18: Net debt, leverage and cash flow
Net Debt at 12/31/16 of $1,374 million comprised of: – Cash on hand of $63 million – $687 million of term loan and revolver – $750 million of bonds Leverage ratio(3) of 4.3x, below 5.0x at the beginning of FY 17 Pro-forma leverage of 5.7x expected at year end FY 17 including acquisition of C.B
Slide 19: IV. FY 17 Outlook
IV. FY 17 Outlook Summers &ve Drama ane Len : cer @D Bvionsrar
Slide 20: FY 17 outlook
Revenue growth remains +4.5% to +6.0% for the year — Q3 YTD Actual +7.2% — Includes impact of divested brands — Continuing to expect organic growth of +1.5% to +2.0% in second half Expect high end of $2.30 to $2.36 range Adjusted Free Cash Flow of $190 million or more * Excludes impact of C.B.
Slide 21: Appendix
—— Third Quarter FY 17 Results PrestigeBrands 2:
Slide 22: Non-GAAP footnotes
(1) Organic Revenue Growth on a constant currency basis is a Non-GAAP financial measure and is reconciled to its most closely related GAAP financial measure in our earnings release in the “About Non-GAAP Financial Measures” section. (2) Adjusted G&A, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted
Slide 23: Organic revenue reconciliation
Three Months Ended Dec. 31, Nine Months Ended Dec. 31, 2016 2015 2016 2015 (In Thousands) GAAP Total Revenues 216,763$ 200,195$ 641,390$ 598,392$ Adjustments: DenTek revenues (17,327) - (51,168) - Revenues associated with divested brands - (6,636) - (13,542) Total adjustments (17,327) (6,636) (51,16
Slide 24: Adjusted G&A reconciliation
Three Months Ended Dec. 31, Nine Months Ended Dec. 31, 2016 2015 2016 2015 (In Thousands) GAAP General and Administrative Expense 22,131$ 18,135$ 60,383$ 52,186$ Adjustments: Costs Associated with CEO transition - - - 1,406 Legal and professional fees associated with acquisitions and divestitures 2,
Slide 25: Adjusted EBITDA reconciliation
Three Months Ended Dec. 31, Nine Months Ended Dec. 31, 2016 2015 2016 2015 (In Thousands) GAAP Net (Loss) Income 31,641$ 27,995$ 58,305$ 85,971$ Interest expense, net 18,554 19,462 60,511 62,013 (Benefit) provision for income taxes 19,092 15,186 33,743 46,611 Depreciation and amortization 5,852 6,07
Slide 26: Adjusted EPS reconciliation
Three Months Ended Dec. 31, Nine Months Ended Dec. 31, 2016 2015 2016 2015 Net Income EPS Net Income EPS Net Income EPS Net Income EPS (In Thousands) GAAP Net Income 31,641$ 0.59$ 27,995$ 0.53$ 58,305$ 1.09$ 85,971$ 1.62$ Adjustments: Costs associated with CEO transition - - - - - - 1,406 0.03 Legal
Slide 27: Adjusted free cash flow reconciliation
Three Months Ended Dec. 31, Nine Months Ended Dec. 31, 2016 2015 2016 2015 (In Thousands) GAAP Net (Loss) Income 31,641$ 27,995$ 58,305$ 85,971$ Adjustments: Adjustments to reconcile net (loss) income to net cash provided by operating activities as shown in the Statement of Cash Flows 3,978 19,119 7
Slide 28: FY 2017 projected EPS and free cash flow reconciliation
2017 Projected EPS Low High Projected FY'17 GAAP EPS $ 1.55 $ 1.61 Adjustments: Costs associated with DenTek integration 0.08 0.08 Loss on divestitures 0.67 0.67 Total Adjustments 0.75 0.75 Projected Non-GAAP Adjusted EPS $ 2.30 $ 2.36 2017 Projected Free Cash Flow (In millions) Projected FY'17 GAAP
Prestige Brands Holdings — Q3 FY2017 Earnings Presentation on 6ix